Published on
February 22, 2021

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Novamind included as fast entry addition to the North American Psychedelics Index, the underlying index of the Horizons Psychedelic Stock Index ETF

TORONTO, ON / ACCESSWIRE / February 22, 2021 / Novamind Inc. (CSE:NM | OTC PINK:NVMDF) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has been selected to be included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) (the "ETF").

Novamind achieves this milestone less than two months after going public on January 5th, 2021. The Company was added to the ETF via a ‘Fast Entry' category, which allows the ETF to add new stocks shortly after they become publicly available, assuming they qualify, including a requirement for a minimum float market capitalization in excess of CAN $50 million.

The ETF seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry.

Novamind's inclusion in the ETF was publicized after market on Friday February 19th, 2021, the same day the Company announced its shares would begin trading under the symbol "NVMDF" on the OTC Market.

"Novamind's inclusion in the first psychedelic ETF is a result of our Company's leadership in mental healthcare and clinical research for psychedelic medicine," commented Yaron Conforti, CEO and Director of Novamind. "We're excited to increase our profile with retail and institutional investors and to share our successful operating model for psychedelic medicine."

For further information on the North American Psychedelics Index (PSYK) click here.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Contact Information

Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.